nos: 91 -98 BACKGROUND Portico Ò (St. Jude Medical) and CoreValveÔ (Medtronic) are both nitinol based self-expanding transcatheter heart valves with unique features enabling device retrievability for Portico and supra annular valve position for CoreValve systems. In this study, we sought to investigate the effect of the different self-expanding valve design on hemodynamic and clinical performance when implanted for degenerated aortic valve bioprosthesis (valve in valve, ViV).
RESULTS A total of 135 patients that underwent ViV using a selfexpanding device were included in the analysis (age 79AE8yrs, 61.5% female). The group included 45 Portico implantations that were matched with 90 CoreValve ViV patients having similar patient and surgical valve characteristics. Baseline demographic and procedural characteristics, echocardiographic and clinical outcomes are detailed in the table. There were no differences in any procedural characteristics between the two groups, except for the external transcatheter valve diameter selected being significantly greater for the CoreValve ViV and proportion of patients undergoing procedure under general anesthesia and with TEE guidance, which was significantly higher for the Portico group. Clinical outcomes were similar except for major vascular complications that were significantly lower in Portico implantations. Site reported echocardiographic parameters showed a greater proportion of patients with more than mild aortic insufficiency after the procedure and a smaller effective orifice area for the Portico compared to CoreValve group. Blinded core lab analysis of post implantation imaging of all cases analyzed is being completed.
CONCLUSIONS Despite important design differences between the two self-expanding transcatheter valves, both devices were safe and effective for management of degenerated aortic bioprosthesis. The present study has identified dissimilarities in hemodynamic performance and clinical outcomes that require confirmation in future studies. CONCLUSIONS Among those with reduced baseline GFR, TAVR results in an improvement in GFR in a substantial portion of patients. Improvement in GFR following TAVR is independently associated with a reduction in all-cause 1-year mortality in patients with severely symptomatic AS who are at high surgical risk or are inoperable. 
